Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

8.14
-0.2600-3.10%
Volume:628.09K
Turnover:5.19M
Market Cap:2.08B
PE:-5.41
High:8.40
Open:8.36
Low:8.14
Close:8.40
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:0.29
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-4.58
PE(LYR):6.73

Loading ...

BioCryst Pharmaceuticals Q1 Operating Expenses USD 858.011 Million

THOMSON REUTERS
·
May 06

BioCryst Pharmaceuticals Q1 Product Sales USD 3.016 Million

THOMSON REUTERS
·
May 06

Corrected-BioCryst Pharmaceuticals Q1 Product Sales USD 148.3 Million (Corrects Amount)

THOMSON REUTERS
·
May 06

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
May 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 06

Top News Today: Stocks Rise, Oil Falls, as War Restart Fears Subside

Dow Jones
·
May 06

BioCryst grants 61,750 RSUs to six new hires under inducement plan

Reuters
·
May 05

BioCryst licenses navenibart Europe rights to Neopharmed Gentili affiliate for $70 million upfront

Reuters
·
May 04

BioCryst Pharmaceuticals Inc - to Receive Tiered Royalties of 18%-30% on Net Sales

THOMSON REUTERS
·
May 04

BioCryst Pharmaceuticals Inc - to Receive $70 Mln Upfront and up to $275 Mln in Milestone Payments

THOMSON REUTERS
·
May 04

BioCryst Pharmaceuticals Inc - Navenibart Phase 3 Program on Track for US Regulatory Filing by End of 2027

THOMSON REUTERS
·
May 04

BioCryst Announces European Licensing Agreement With Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

THOMSON REUTERS
·
May 04

Earning Preview: Biocryst Pharmaceuticals this quarter’s revenue is expected to increase by 19.12%, and institutional views are broadly bullish

Earnings Agent
·
Apr 30

BioCryst Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 24

Tenax Therapeutics names Thomas R. Staab CFO, replacing interim CFO Thomas McGauley

Reuters
·
Apr 22

Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and BioCryst (BCRX)

TIPRANKS
·
Apr 16

BioCryst to report first-quarter financial results, host conference call and webcast

Reuters
·
Apr 15

A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New R&D Leadership Appointment

Simply Wall St.
·
Apr 09